Skip to main content
. Author manuscript; available in PMC: 2012 Oct 26.
Published in final edited form as: Cancer Chemother Pharmacol. 2011 Apr 9;68(6):1439–1447. doi: 10.1007/s00280-011-1637-5

Table 2.

Renal dysfunction groups and bortezomib doses administered

Number of
patients		 Bortezomib cycles CrCl (mL/min/1.73 m2)
Number Mean Range Mean SD
Normal renal function 15
1.3 mg/m2 14 98 7 1–37 93.9 23.4
1.5 mg/m2 1 1 1 NA 91.1 NA
Mild renal dysfunction 17
1 mg/m2 3 8 3 2–4 51.8 8.8
1.3 mg/m2 14 32 2 1–5 47.4 6.0
Moderate renal dysfunction 18
0.7 mg/m2 4 20 5 2–8 28.7 2.2
1 mg/m2 3 30 10 3–23 36.0 3.8
1.3 mg/m2 11 39 4 1–12 31.9 6.8
Severe renal dysfunction 3
0.7 mg/m2 3 4 1 1–2 14.7 4.7
1 mg/m2 0 0 NA NA NA NA
1.3 mg/m2 0 0 NA NA NA NA
Dialysis 9
0.7 mg/m2 3 6 2 NA NA NA
1 mg/m2 2 6 3 2–4 NA NA
1.3 mg/m2 4 19 4.7 2–12 NA NA